EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity

Sohyon Lee, Tobias Weiss, Marcel Bühler, Julien Mena, Zuzanna Lottenbach, Rebekka Wegmann, Miaomiao Sun, Michel Bihl, Bartłomiej Augustynek, Sven P Baumann, Sandra Goetze, Audrey van Drogen und 13 weitere

Nature Medicine · 2024-11 · 30 (11) · 3196-3208

DOI: 10.1038/s41591-024-03224-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nature Medicine, online erschienen am 20.09.2024. Verfasst von Sohyon Lee und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - E…, European Molecular Biology Organization (EMBO), Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma, the most aggressive primary brain cancer, has a dismal prognosis, yet systemic treatment is limited to DNA-alkylating chemotherapies. New therapeutic strategies may emerge from exploring neurodevelopmental and neurophysiological vulnerabilities of glioblastoma. To this end, we systematically screened repurposable neuroactive drugs in glioblastoma patient surgery material using a clinically concordant and single-cell resolved platform. Profiling more than 2,500 ex vivo drug responses across 27 patients and 132 drugs identified class-diverse neuroactive drugs with potent anti-glioblastoma efficacy that were validated across model systems. Interpretable molecular machine learning of drug–target networks revealed neuroactive convergence on AP-1/BTG-driven glioblastoma suppression, enabling expanded in silico screening of more than 1 million compounds with high patient validation accuracy. Deep multimodal profiling confirmed Ca 2+ -driven AP-1/BTG-pathway induction as a neuro-oncological glioblastoma vulnerability, epitomized by the anti-depressant vortioxetine synergizing with current standard-of-care chemotherapies in vivo. These findings establish an actionable framework for glioblastoma treatment rooted in its neural etiology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsHumansHigh-Throughput Screening AssaysAnimalsAntineoplastic AgentsDrug RepositioningCell Line, TumorMice

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland.
  • Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
  • Institute of Pathology, University Hospital Zurich, Zurich, Switzerland.
  • Membrane Transport Discovery Lab, Department of Nephrology and Hypertension and Department of Biomedical Research, Inselspital, University of Bern, Bern, Switzerland.
  • Institute of Biochemistry and Molecular Medicine, University of Bern, Bern, Switzerland.
  • Department of Health Sciences and Technology, Institute of Translational Medicine (ITM), ETH Zurich, Zurich, Switzerland.

Förderung

  • EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - E…
  • European Molecular Biology Organization (EMBO)
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation)

Zitieren

APA

Lee, S., Weiss, T., Bühler, M., Mena, J., Lottenbach, Z., Wegmann, R., Sun, M., Bihl, M., Augustynek, B., Baumann, S. P., Goetze, S., van Drogen, A., Pedrioli, P. G. A., Penton, D., Festl, Y., Buck, A., Kirschenbaum, D., Zeitlberger, A. M., Neidert, M. C., …, & Snijder, B. (2024). High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity. Nature Medicine, 30(11), 3196-3208. https://doi.org/10.1038/s41591-024-03224-y

Vancouver

Lee S, Weiss T, Bühler M, Mena J, Lottenbach Z, Wegmann R, et al. High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity. Nature Medicine. 2024;30(11):3196-3208. doi:10.1038/s41591-024-03224-y

BibTeX
@article{Lee2024,
  author = {Lee, Sohyon and Weiss, Tobias and Bühler, Marcel and Mena, Julien and Lottenbach, Zuzanna and Wegmann, Rebekka and Sun, Miaomiao and Bihl, Michel and Augustynek, Bartłomiej and Baumann, Sven P and Goetze, Sandra and van Drogen, Audrey and Pedrioli, Patrick G A and Penton, David and Festl, Yasmin and Buck, Alicia and Kirschenbaum, Daniel and Zeitlberger, Anna M and Neidert, Marian C and Vasella, Flavio and Rushing, Elisabeth J and Wollscheid, Bernd and Hediger, Matthias A and Weller, Michael and Snijder, Berend},
  title = {High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity},
  journal = {Nature Medicine},
  year = {2024},
  volume = {30},
  number = {11},
  pages = {3196--3208},
  doi = {10.1038/s41591-024-03224-y}
}
Kostenlos starten →